A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know

Jonathan Sheena, a co-founder of Natera, Inc. (NASDAQ:NTRA), sold 9,150 shares of common stock at $315.66 per share on August 7, according to an SEC Form 4 filing.

Transaction summary

Metric	Value
Shares sold	9,150
Transaction value	$2.9 million
Post-transaction shares (directly held)	236,464
Post-transaction value	$81.97 million

Transaction value based on SEC Form 4 weighted average sale price ($315.66); post-transaction value based on the August 7 market close ($322.10).

Key questions

• How does this transaction align with the insider's long-term trading strategy?
  This sale was conducted via a Rule 10b5-1 trading plan established in December 2025, which allows insiders to diversify their portfolios through pre-scheduled transactions that occur regardless of subsequent market movements.
• What is the scale of the insider's remaining equity exposure?
  Sheena retains a significant equity stake valued at $81.97 million as of the August 7 market close, representing 0.2% of the company's total shares outstanding.
• What has been the performance context for Natera leading up to this sale?
  The stock has delivered a 128% one-year total return as of the August 7 transaction date, during which time the company reported trailing-12-month revenue of $2.7 billion and a net income loss of $192.3 million.

Company Overview

Metric	Value
Share Price (as of market close 2026-08-06)	$265.38
Market Capitalization	$46.1 billion
Revenue (TTM)	$2.7 billion
Net Income (TTM)	-$192.3 million

Company Snapshot

• Natera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama for non-invasive prenatal testing, Vistara for single-gene disorder screening, and Horizon for carrier screening, generating revenue through test ordering and processing services.
• The company operates a diagnostics-as-a-service business model, leveraging proprietary molecular testing technology to process patient samples and deliver clinical results to healthcare providers, with revenue derived from per-test fees and volume-based arrangements.
• Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors, with primary customers including fertility clinics, prenatal care providers, and healthcare systems seeking comprehensive genetic and reproductive health screening solutions.

Natera is a leading global diagnostics company with a market capitalization of $46.1 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the molecular diagnostics sector. The company's competitive advantage derives from its proprietary testing platforms and extensive clinical validation data, enabling it to address critical unmet needs in prenatal, carrier, and reproductive health screening. Despite current net losses, Natera's substantial revenue base and market valuation reflect investor confidence in its growth trajectory and the expanding addressable market for non-invasive genetic testing.

What this transaction means for investors

A co-founder selling is the kind of filing that might make shareholders flinch, but the calendar drains most of the meaning from this one, since Sheena's sale ran on a plan set back in December and simply happened to execute as Natera surged to record territory after earnings. In other words, he sold into strength rather than weakness and kept a stake worth about $82 million, and the trade reflects a schedule set eight months ago, all of which signals that this isn’t at all a read on the stock.

The surge she sold into was earned. Natera grew second-quarter revenue about 38% to $753 million, far past what Wall Street expected, driven by its Signatera cancer-detection test, whose clinical volume jumped 56%. The company raised full-year guidance by $100 million and won a string of regulatory approvals for Signatera across bladder and colorectal cancer. CFO Mike Brophy said guidance "assumes stable Signatera pricing" for the rest of the year. The part worth weighing is that Natera still loses money, spending heavily on early cancer detection that adds no revenue yet, so the stock now prices in a profitable future the income statement has not reached. But if execution continues, there could certainly be room for the stock to run.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.